Natco will fix its own price for the generic versions, and will pay a royalty on sales to Gilead, the company said.
Natco Pharma Limited said on Monday it signed a licensing deal with Gilead Sciences Inc to make and sell generic versions of the US drugmaker's chronic hepatitis C medicines.
Drugs under the deal include sofosbuvir, a combination of ledipasvir and sofosbuvir, and GS-5816, which is in late-stage clinical trials, Natco said in a statement.
Natco will fix its own price for the generic versions, and will pay a royalty on sales to Gilead, the company said.
Natco Pharma stock price
On March 02, 2015, at 14:15 hrs Natco Pharma was quoting at Rs 1414.00, up Rs 45.30, or 3.31 percent. The 52-week high of the share was Rs 1586.25 and the 52-week low was Rs 655.55.
The company's trailing 12-month (TTM) EPS was at Rs 33.85 per share as per the quarter ended December 2014. The stock's price-to-earnings (P/E) ratio was 41.77. The latest book value of the company is Rs 217.49 per share. At current value, the price-to-book value of the company is 6.50.
Anda sedang membaca artikel tentang
Natco Pharma ties up with Gilead on hepatitis C drugs
Dengan url
https://kesehatanda.blogspot.com/2015/03/natco-pharma-ties-up-with-gilead-on.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Natco Pharma ties up with Gilead on hepatitis C drugs
namun jangan lupa untuk meletakkan link
Natco Pharma ties up with Gilead on hepatitis C drugs
sebagai sumbernya
0 komentar:
Posting Komentar